中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

替比夫定治疗HBeAg阳性慢性乙型肝炎的疗效及相关预测因子的Logistic回归分析

郭如意 余雪平 苏智军 林成祖 林志鹏 林琪

引用本文:
Citation:

替比夫定治疗HBeAg阳性慢性乙型肝炎的疗效及相关预测因子的Logistic回归分析

基金项目: 

2008年泉州市科技计划项目(2008Z36); 

详细信息
  • 中图分类号: R512.62

Evaluation of telbivudine’s efficacy for treating HBeAg-positive chronic B hepatitis patients and identification of its predictive factors by logistic regression analysis

Research funding: 

 

  • 摘要:

    目的观察替比夫定(LdT)治疗HBeAg阳性慢性乙型肝炎(CHB)患者3年的疗效,应用Logistic回归探讨HBeAg血清学转换的预测因子。方法收集58例采用LdT治疗的HBeAg阳性CHB患者,分析其性别、年龄、基线ALT水平、基线HBV DNA载量、基线HBeAg和HBsAg滴度与治疗3年时ALT复常率、HBV DNA阴转率、HBeAg阴转率和HBeAg血清转换率的相关性;采用Logistic回归分析HBeAg血清转换的相关因素。结果治疗3年时ALT复常率为84.48%,HBV DNA阴转率为70.69%,HBeAg阴转率为50.00%,HBeAg血清转换率为43.10%。与ALT≤2倍正常值上限(2×ULN)相比,基线ALT>5×ULN的患者HBeAg转换率显著增高(P<0.05);与hbeag≤100(s hbeag="">200 S/CO的患者HBeAg的阴转率和血清转换率均显著下降(P<0.05);与hbv 6="" hbv="" dna="">7 log拷贝/ml的患者HBV DNA转阴率、HBeAg转阴率和HBe...

     

  • [1] Chinese Society of Hepatology and Chinese Society of Infec-tious Diseases, Chinese Medical Association.The guidelineof prevention and treatment for chronic hepatitis B[J].JChin Hepatol, 2006, 22 (1) :3-15. (in Chinese) 中华医学会肝病学分会, 感染病学分会.慢性乙型肝炎防治指南[J].临床肝胆病杂志, 2006, 22 (1) :3-15.
    [2]Tacke F, Trautwein C.Hepatitis B goes globe:Telbivudine asa new treatment option[J].Hepatology, 2008, 47 (5) :1786-1787.
    [3]Jia JD, Hou JL, Yin YK, et al.The degree of HBV suppres-sion with 24 week telbivudine-or lamivudine-treatment inhepatitis B patients predicts the efficacy of the treatment atweek 52[J].Chin J Hepatol, 2007, 15 (5) :342-345. (inChinese) 贾继东, 侯金林, 尹有宽, 等.替比夫定或拉米夫定抗乙型肝炎病毒的疗效预测探讨[J].中华肝脏病杂志, 2007, 15 (5) :342-345.
    [4] Huang J, Chen XP, Chen XF, et al.Study on the efficacy andHBeAg seroconversion related factors of telbivudine and ente-cavir therapy in HBeAg positive chronic hepatitis B patients[J].Chin J Hepatol, 2011, 19 (3) :178-181. (in Chinese) 黄晶, 陈小苹, 陈学福, 等.慢性乙型肝炎的疗效及HBeAg血清学转换的预测因素[J].中华肝脏病杂志, 2011, 19 (3) :178-181.
    [5]He CL.Evaluation of effectiveness of oral antiviral drugs for chron-ic hepatitis B[J].Chin Hepatol, 2008, 13 (2) :154-157. (in Chi-nese) 何长伦.慢性乙型肝炎的口服抗病毒药物评价[J].肝脏, 2008, 13 (2) :154-157.
    [6]Chien RN, Liaw YF.Short-term lamivudine therapy in HBeAg-negative chronic active hepatitis B in Taiwan[J].Antivir Ther, 2006, 11 (7) :947-952.
    [7]Wan MB.The expert panel symposinm on treatment for chronichepatitis B with lamivudine[J].Chin Hepatol, 2009, 14 (2) :167-169.
    [8]Yao QJ, Ma WG.Therapeutic ef cacy of telbivudine in hepa-titis B e antigen positive chronic hepatitis B patients with highbaseline alanine aminotransferase levels[J].J Chin Hepatol, 2011, 27 (6) :614-616. (in Chinese) 姚钦江, 马卫国.替比夫定治疗高ALT水平HBeAg阳性慢性乙型肝炎的临床观察[J].临床肝胆病杂志, 2011, 27 (6) :614-616.
    [9]Xu HX, Yu YX, Zhang MX, et al.Application of telbivudineand entecavir in the treatment of patients with HBeAg-posi-tive chronic hepatitis B[J].J Clin Hepatol, 2011, 14 (4) :265-267. (in Chinese) 徐鹤翔, 余亚新, 张明侠, 等.替比夫定和恩替卡韦治疗HBeAg阳性慢性乙型肝炎患者早期疗效分析[J].实用肝脏病杂志, 2011, 14 (4) :265-267
    [10]EASL Clinical Practice Guidelines:Management of Chronic Hep-atitis B[J].J Hepatol, 2009, 50 (2) :233-242.
  • 加载中
计量
  • 文章访问数:  3589
  • HTML全文浏览量:  10
  • PDF下载量:  807
  • 被引次数: 0
出版历程
  • 出版日期:  2013-02-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回